amendment of the assignment agreement. 2. 1 amendment of first sentence of section 6. 3 ( a ). the first sentence of section 6. 3 ( a ) of the assignment agreement is hereby amended to read as follows : pharmacyc1ics will pay to celera payments as set forth in this section 6. 3 within sixty ( 60 ) days after ( i ) under section 6. 3 ( b ) and 6. 3 ( c ), pharmacyclics'receipt of upfront and milestone payments from one or more licensees upon the grant by pharmacyclics of a license to such licensee under the celera technology and the celera patents to make, use, offer to sell, sell and import any assigned product which is an [ * * * ], and ( ii ) under section 6. 3 ( d ), the first achievement of the corresponding milestone for an assigned product which is an [ * * * ] or which is a [ * * * ]. 2. 2 amendment of section 6. 3 ( d ). in the event that pharmacyclics and [ * * * ] ( " [ * * * ] " ) enter into an agreement within [ * * * ] ( [ * * * ] ) days of the amendment date pursuant to which pharmacyclics grants to [ * * * ] a license to make, use, offer to sell, sell and import one or more [ * * * ] ( " [ * * * ] license agreement " ), then section 6. 3 ( d ) of the assignment agreement shall be, and hereby is, amended as follows : the milestone payment due for an [ * * * ] upon achievement of milestone 1 ( " administration of an assigned product to the first patient in a phase 3 clinical trial " ) is reduced to [ * * * ] dollars ( $ [ * * * ] ) ; a new milestone payment applicable to an [ * * * ] ( milestone 1a ), in the amount of [ * * * ] dollars ( $ [ * * * ] ), will be due upon enrollment of the last subject in the phase 3 clinical trial. the milestone payments due for an [ * * * ] upon achievement of milestone 6 ( " regulatory approval in [ * * * ] of an nda for an assigned product for a second indication " ) and milestone 7 ( " regulatory approval in [ * * * ] of an nda for an assigned product for a second